leisure time -WSS

leisure time

author：fashion 2025-10-02 21:00:42 - browse：43664

James Comer -- coverage from STAT — Rep. James Comer, chair of the House Oversight Committee Kevin Dietsch/Getty Images

WASHINGTON — Congress wants to reform PBM business practices to help lower the cost of medicines — but don’t think they’ve forgotten drugmakers have a role in high drug prices.

Two lawmakers, including a Republican, questioned PhRMA Chief Operating Officer Lori Reilly about just how much her group was spending on its major campaigns against PBMs this year. Both Reps. Summer Lee (D-Pa.) and Eric Burlison (R-Mo.) used their time to question drugmakers over their spending on lawsuits against Medicare drug price negotiation and ad campaigns against pharmacy benefit managers.

Although Lee started off bashing PBMs for the fees they charge drugmakers, she quickly aimed her fire back on pharma. She said brand drugmakers charge Americans double what they charge other countries, and she asked why several drugmakers are suing the federal government over Medicare’s drug price negotiation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Medicare drug price lawsuits could be good politics for Biden

entertainment

focus

WSS

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

There's an unseen cost to disruptive road

TikTok, Instagram influencers need more rules for drug ads

3 trends to watch in health tech's hiring outlook for 2024

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Medicare drug price lawsuits could be good politics for Biden

hotspot

leisure time

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

Why psychiatrists like me stop taking insurance

BioMarin wins approval for gene therapy to treat hemophilia A

How a scoliosis diagnosis changed the life of one young dancer

In Memoriam: Notable people who died in 2023

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Continuity nursing helped my family in our darkest PICU moments

Microsoft launches AI tool for clinical documentation through Epic

Medical leaders decry Supreme Court decision on affirmative action

High breast density mammograms need follow

entertainment

How a scoliosis diagnosis changed the life of one young dancer

Why psychiatrists like me stop taking insurance

Maisha Meds is a PBM, but don't call it that

The biotech scorecard for Q1: 17 stock

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

To bolster infectious disease surveillance, genomics powerhouses team up

leisure time

entertainment

focus

hotspot